6236.TWO Neith Corporation
- Market cap
- TWD 625M
- P/E
- 1,500.0x
- P/B
- 4.45x
- ROE
- -0.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6236.TWO undervalued?
Graham numberThe Graham number of Neith Corporation cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Neith Corporation fundamental analysis
No fundamental analysis for Neith Corporation yet.
Neith Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Neith Corporation
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company provides nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; and other nutritional products under the King One name. It also offers genetic testing services. In addition, the company offers energy and dual-purpose mattresses, energy masks, energy silicon gel necklaces, energy waistbands, energy…
Full company profileNeith Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Neith Corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 31.4M | 32.1M | 39.9M | 45.6M | 36.1M | 32.1M |
| Gross Profit | 14.5M | 13.4M | 18.0M | 33.7M | 30.2M | 26.7M |
| Operating Income | -9.20M | -29.1M | -48.9M | -24.9M | -923K | -2.30M |
| EBITDA | - | -18.5M | -33.6M | -12.1M | 7.84M | 4.45M |
| Net Income | -5.35M | -23.7M | -40.0M | -16.9M | 3.16M | -104K |
| EPS | -0.17 | -0.57 | -0.96 | -0.41 | 0.08 | 0.00 |
| Balance Sheet | ||||||
| Total Assets | 76.8M | 229M | 192M | 171M | 168M | 167M |
| Total Liabilities | 5.08M | 20.4M | 17.4M | 16.6M | 13.1M | 11.0M |
| Shareholders' Equity | 71.7M | 208M | 175M | 154M | 155M | 156M |
| Cash & Short-term Investments | 36.1M | 182M | 154M | 133M | 141M | 139M |
| Cash Flow | ||||||
| Operating Cash Flow | 7.47M | -26.5M | -17.6M | -28.0M | 9.29M | -1.61M |
| Capital Expenditure | 1.50M | 7.71M | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 5.96M | -34.2M | -17.6M | -28.0M | 9.29M | -1.61M |
| Ratios | ||||||
| ROE | -7.5% | -11.4% | -22.9% | -10.9% | 2.0% | -0.1% |
| ROA | -7.0% | -10.4% | -20.8% | -9.9% | 1.9% | -0.1% |
| Net Profit Margin | -17.1% | -73.9% | -100.3% | -37.0% | 8.7% | -0.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Neith Corporation dividends
Neith Corporation has not paid dividends in the last 5 fiscal years.
Last stock split: 0.21:1 on Feb 12, 2008.
Who owns Neith Corporation
- Insiders 91.28%
- Institutions 0.00%
- Public & others 8.72%
- Shares outstanding 41.7M
- Free float 5.05M
Neith Corporation company profile
- Company name
- Neith Corporation
- Ticker
- 6236.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 51, GongYi Road, Taichung, Taiwan, 408
- Phone
- 886 4 2328 1939
- Website
- neithcorp.com
About Neith Corporation
Neith Corporation engages in the biotechnology, medical cosmetics, and preventive medicine businesses. The company provides nutritional products, including L-One, a liquid formula for maintaining eye health; EPlus, a multiple enzyme supplement; and other nutritional products under the King One name. It also offers genetic testing services. In addition, the company offers energy and dual-purpose mattresses, energy masks, energy silicon gel necklaces, energy waistbands, energy heating stones, massage rods, and water purifiers, as well as Ganbanyoku, an energy stone spa bed. Further, it offers beauty care products, such as cell regeneration and rejuvenation series skin care products; home energy products; and microcontrollers and peripherals. Neith Corporation was formerly known as Come True Biomedical Inc. Neith Corporation was incorporated in 1997 and is based in Taichung, Taiwan.
Neith Corporation management
2- Yuefeng LinChairman of the Board of Directors & Manager
- Yi Fang WuAccounting Supervisor